Alvotech Moves Forward As Aflibercept Filing Lands On EMA’s Desk

Icelandic Firm Vying For Potential 2025 Approval; Advanz Main EU Commercial Partner

 
• By Dean Rudge

Alvotech and its partners Advanz and Biogaran have welcomed acceptance in Europe for the Icelandic firm’s filing for a proposed biosimilar to Eylea 2mg, as another player makes its move.

perfect blue eye macro in a sterile environment and perfect vision in resolution 6k, concept, the vision of the future and healthy life concept. view precise and straight to the target.
• Source: Shutterstock

More from Biosimilars

More from Products